Key Highlights

  • Total Revenue was USD 33.6 million against an estimate of USD 31.40 million and USD 29.4 million last year.
  • Loss per share of USD 0.68 compares with USD 0.69 estimated; GAAP net loss per share was USD 0.78.
  • Gross Margin was 40.7% against 39.4%, and net loss was USD 14.7 million against USD 17.8 million.
  • Cash, restricted cash and short-term investments were USD 140.7 million, alongside a USD 100 million Perceptive term loan.

Outset Medical, Inc. (NASDAQ:OM) frames its Business around the Tablo Hemodialysis System, a compact console that needs only an electrical outlet and tap water and is cleared by the FDA for hospital, clinic and home use. For the third quarter, total revenue was USD 33.6 million against USD 29.4 million a year earlier and an estimate of USD 31.40 million. Loss per share of USD 0.68 compares with an estimate of USD 0.69.

Stated Priorities: Acute Care, Post-Acute Providers and Home

Management described driving adoption of Tablo in the acute care setting as its primary focus to date. It is also working with skilled nursing facilities, long-term acute care hospitals and other post-acute providers, and it plans to use its existing commercial infrastructure to broaden the installed base and drive utilization and fleet expansion with current customers. In the home market, the company said it continues to refine distribution, logistics and support systems and to promote transitional care units as a bridge to home-based therapy.

A single sales organization serves both acute and home markets. The company described customers deferring purchases amid higher interest rates and cautious Capital spending, which it said has weighed on bookings and revenue since the second half of 2023.

Financial Results: Product, Service and Margins

Product revenue was USD 23.7 million against USD 20.6 million, which the company attributed to a USD 2.1 million increase in console revenue and a USD 1.0 million increase in consumable revenue. Service and other revenue was USD 9.9 million against USD 8.9 million, tied to services for the growing console installed base.

Gross profit was USD 13.7 million against USD 11.6 million, and gross margin was 40.7% against 39.4%, which the company linked to higher margin on service and other revenue, offset in part by a lower mix of consumable revenue. Operating expenses were USD 25.9 million against USD 27.4 million, with sales and Marketing at USD 11.7 million against USD 13.6 million. Loss from operations was USD 12.3 million against USD 15.8 million.

Net loss was USD 14.7 million, or USD 0.78 per share, against USD 17.8 million, or USD 1.00 per share. Nine-month net loss was USD 51.6 million against USD 62.2 million.

Cash, Debt and Capital Resources

At September 30 the company had USD 140.7 million of cash, cash equivalents, restricted cash and short-term investments. Nine-month operating cash use was USD 32.9 million against USD 36.8 million. Under the Perceptive Credit agreement it received a USD 100 million five-year term loan, and it may elect an additional term Loan of up to USD 25 million, available until July 14, 2027 and subject to a specified revenue milestone as amended in August 2026.

Management said existing cash, short-term investments and cash from sales cover its needs for at least 12 months, while noting it continues to incur operating losses and may raise additional capital. The company gave no numeric guidance.

Dates and Milestones Named

Revenue of USD 33.6 million sits alongside a 40.7% gross margin, a loss of USD 0.78 per share on a GAAP basis and USD 140.7 million of cash and short-term investments.

Management named a July 14, 2027 availability date for the delayed-draw term loan, the August 2026 five-year extension of the Lease for its Tijuana, Mexico Manufacturing facility, and its stated priorities of broadening the acute and post-acute installed base, growing home programs and optimizing operating expenses and working capital.